President's Message


It is with great pleasure that I welcome you to our 2nd issue of CFForward. As of January 1, 2013, I took the reins from my colleague Timothy Clark as Board President. I would like to take this opportunity to thank Tim for his tireless service on behalf of our constituents. We all learned a great deal from Tim and we are grateful that he plans to stay involved with our Greater New York Chapter.

I would also like to acknowledge those Board members who have fulfilled their term commitment and are rotating to the Board of Advisors for the coming year: Marc Cassalina, Timothy Clark, Jon Cummins, Tom Grotta, Alan Hartman, Tom Lynch, John McMahon, Robert O’Mahony and Robert Shafir. Their collective contribution to our cause is immeasurable and we are deeply thankful to each of them.

We are well on our way to filling their shoes, and I would like to introduce three new members who have joined the Board in 2013: Jeffrey Rose, Dr. Emily DiMango and Brad Scott.  They bring a diverse set of skill, knowledge and relationships and we warmly welcome them.

We set off into 2013 with great momentum!  After all, 2012 was a record-breaking year for the Greater New York Chapter.  Together, we raised $12.3 Million for CF research.  To recap a few of our Chapter highlights:

  • Great Strides, our largest fundraising event, with 10 walks throughout Greater New York, raised $3.2 Million in 2012.
  • In its 2nd year, Partners In Progress, our annual fund campaign, raised nearly $140,000.
  • Also in its 2nd year, Milestones II Campaign, our major gift program, raised $5.9 Million.
  • Galas, golf outings, CF Cycle for Life, and other events raised $3,151,000.

In the grander scheme of things, it is an exhilarating time to be involved with the CFF.  2012 was truly a breakthrough year for the CF community on many levels.   The FDA approved Kalydeco™, the first drug to treat the underlying cause of CF. While Kalydeco is currently approved to treat only 4% of CF patients, this achievement will serve as a catalyst to develop effective treatments for all people living with CF.  It will help us draw the scientific talent, capture the pharmaceutical company interest, and drive the fundraising efforts needed to get from 4% to 100%!

As we move into 2013, it is critical that we build on the current momentum and capitalize on these opportunities. While we have more clarity on where we are going and resources coming to bear than ever before, we have a long way to go.  We are all justified in feeling more hopeful than ever, but as hope becomes reality, we must press hard to finish the job!  To that end, millions of dollars have been committed to continue the CF Foundation model of “venture philanthropy.” Remember,   “Money buys science and science saves life.

With Spring upon us, and with a robust Great Strides goal of $3.5 million for 2013, we hope you will join Great Strides 2013.  We are once again hosting 10 walks and with your support we know we can reach our goal.    I hope to see you out there!


John A. McKenna, Jr.
President, Board of Directors